Contract research organisation providing ion channel services to the drug discovery market

Metrion Biosciences (Metrion) is a contract research organisation providing ion channel services to the drug discovery market. They serve pharmaceutical and biotech clients to either perform cardiac screening services to understand if novel drug compounds have off-target effects or to develop new drug compounds that utilise ion channels.

Metrion has an experienced team providing a highly specialist service into a structurally growing market.

Investment rationale

Gresham House Ventures invested £2.25m as part of a £2.7m round. The investment will increase capacity, with enlarged lab facilities and specialist equipment; expand their service offering by adding a highly regulated GLP (Good Laboratory Practice) cardiac offering and expand their cell line library; and support further expansion in the United States. The investment continues our focus on outsourcing pharma services.

 

This new investment is a key part of Metrion’s strategic development, enabling the Company to expand its laboratories, provide enhanced services and invest more extensively in US business development. We thank Gresham House for the confidence they have shown in the Metrion team.

- Keith McCullough, Chairman, Metrion Biosciences

Privacy Preference Center